<DOC>
	<DOCNO>NCT02595372</DOCNO>
	<brief_summary>In preliminary laboratory science study , investigator show proton pump inhibitor ( PPIs ) effectively inhibit human fatty acid synthase ( FASN ) breast cancer cell survival . A preliminary retrospective study show PPI usage breast cancer patient chemotherapy significantly improve overall survival . The impact strike patient triple negative breast cancer ( TNBC ) . Thus , PPIs may reposition safe effective breast cancer drug enhance effect chemotherapy . Many hurdle slow progress target , lead compound , investigational agent , standard therapy barrier PPIs . The PPIs FDA-approved , chronically use , well tolerate investigator move quickly laboratory proof concept clinical trial . Incorporating PPIs standard care require investigator propose , investigator already plot additional step need truly impact patient care . If successful , data gather proposal lend support guide development definitive randomize trial .</brief_summary>
	<brief_title>Inhibiting Fatty Acid Synthase Improve Efficacy Neoadjuvant Chemotherapy</brief_title>
	<detailed_description>Primary Objective • Estimate rate pathologic complete response ( pCR ) patient triple negative breast cancer FASN expression treat standard neoadjuvant chemotherapy ( NAC ) combination high dose omeprazole . Secondary Objectives - Quantify number patient newly diagnose TNBC tumor express FASN . - Estimate rate pCR patient triple negative breast cancer ( irrespective FASN status ) treat standard NAC combination high dose omeprazole . - Describe safety incorporate high dose omeprazole standard NAC . - Estimate biologic activity high dose omeprazole modulate FASN expression activity . This single arm Phase II study . Patients begin therapy within 7 work day study entry . Patients treat omeprazole 80 mg orally twice day ( BID ) begin 4-7 day prior chemotherapy continue surgery . After brief period omeprazole monotherapy , patient begin standard neoadjuvant chemotherapy doxorubicin ( 60 mg/m2 ) cyclophosphamide ( 600 mg/m2 ) 4 cycle follow paclitaxel ( 80 mg/m2 ) weekly x 12 . Doxorubicin cyclophosphamide ( AC ) may administer classical every 3 week dose dense every 2 week ( growth factor support ) schedule treat physician 's discretion . Routine incorporation carboplatin recommend , however use carboplatin ( AUC 6 week 1 , 4 , 7 , 10 ) paclitaxel allow treat investigator 's discretion . Chemotherapy adjust base toxicity accord standard treatment guideline . Patients overt disease progression AC move immediately paclitaxel therapy . Patients disease progression paclitaxel proceed immediately surgery .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Inclusion Criteria 1 . Newly diagnose triple negative breast cancer ( TNBC ) clinical stage Ic , II , III ER PR &lt; 10 % HER2 negative base one following : IHC 0 1+ IHC 2+ FISH negative IHC 2+ FISH equivocal indication HER2 target therapy base treat investigator discretion ( i.e. , HER2 : CEP17 ratio &lt; 2.0 HER2 total copy number &lt; 6 ) 2 . Planned neoadjuvant treatment anthracycline taxane contain chemotherapy 3 . ≥ 18 year old time inform consent 4 . ECOG Performance Status 01 5 . Ability provide write informed consent HIPAA authorization 6 . Women childbearing potential definition must negative pregnancy test within 14 day registration . All woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) consider childbearing potential unless meet one follow criterion : Prior hysterectomy bilateral oophorectomy ; Has menses time precede 24 consecutive month 7 . Adequate organ function anthracycline taxane base therapy LVEF &gt; LLN base cardiac ECHO MUGA Hgb &gt; 8.5 ANC &gt; 1,000 Platelets &gt; 100,000 Creatinine &lt; 1.5 T. bili &lt; 1.3 AST &lt; 2.5 x ULN Exclusion Criteria 1 . Use prescription PPIs within 12 month prior study entry [ Dexlansoprazole ( Dexilant ) , Pantoprazole ( Protonix ) , Rabeprazole ( Aciphex ) , Esomeprazole ( Nexium ) , Lansoprazole ( Prevacid ) , Omeprazole ( Prilosec , Zegerid ) ] 2 . Use OTC PPIs within 6 month prior study entry [ Esomeprazole ( Nexium ) , Lansoprazole ( Prevacid ) , Omeprazole ( Prilosec , Zegerid ) ] 3 . Use Orlistat know FASN inhibitor within 6 month prior study entry 4 . Nursing mother exclude 5 . Known hypersensitivity component formulation substitute benzimidazoles 6 . Prior osteoporotic fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>